FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

r	<	ı	3	A	N	J	C	H/	41	IG	C	Ul	VII	VII	5	3	U	ľ

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Perso Brooks Gabriel	n [*]		2. Issuer Name and Ticker or Trading Symbol Solid Biosciences Inc. [SLDB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) C/O SOLID BIOSCIENCES INC. 500 RUTHERFORD AVENUE, T	10/18	3. Date of Earliest Transaction (Month/Day/Year) 10/18/2024						Officer (give title Other (specify below) Chief Medical Officer					
(Street) CHARLESTOWN MA 02129 (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Indir Line)	l <u></u>				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				
Common Stock	10/18/2024		M		9,750	A	(1)	13,902(2)	D				

(e.g., puts, calls, warrants, options, convertible securities) 6. Date Exercisable and Expiration Date 9. Number of derivative 11. Nature of Indirect 1. Title of Derivative 3. Transaction Date 3A. Deemed Execution Date 7. Title and Amount of 8. Price of Derivative 10. Ownership 5. Number 2. Conversion Transaction Security (Instr. 3) (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) Security (Instr. 5) Form: Direct (D) or Indirect or Exercise Derivative (Month/Day/Year) Securities Securities Beneficial Price of Securities Acquired Underlying Derivative Security Beneficially Ownership (Instr. 4) Derivative Owned (A) or Disposed of (D) Following Reported Security (Instr. 3 and 4) (I) (Instr. 4) Transaction(s) (Instr. 3, 4 and 5) (Instr. 4) Amount Number Date Expiration (A) (D) Exercisable Title Shares Restricted 10/18/2024 (4) (4) 9,750 29,250 9,750 \$<mark>0</mark> D Stock Stock

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

2.923(3)

D

\$6.5

10,979

D

Explanation of Responses:

Common Stock

- 1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- 2. Includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024

10/21/2024

- 3. This sale was made to cover withholding taxes following the vesting of the previously granted RSUs.
- 4. The RSUs were granted on October 18, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary

/s/ David Tyronne Howton as attorney-in-fact for Gabriel 10/22/2024 **Brooks**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.